[2024 ESC Guidelines for the management of elevated blood pressure and hypertension] [0.03%]
[2024 ESC高血压管理和血压升高管理指南]
John William McEvoy,Cian P McCarthy,Rosa Maria Bruno et al.
John William McEvoy et al.
Federico Sammartino,Elisabetta Tonet
Federico Sammartino
[Aortic valve dehiscence: the deadly face of prosthetic endocarditis] [0.03%]
人工瓣周心内膜炎致主动脉瓣脱垂并发急性重度二叶式主动脉瓣关闭不全一例报告及文献复习
Catarina Ribeiro Carvalho,Sofia Carvalho,Ana Baptista et al.
Catarina Ribeiro Carvalho et al.
[Epidermal inclusion cyst mimicking an implantable cardiac defibrillator pocket infection: a rare finding] [0.03%]
皮下囊肿误诊为植入型心脏复律除颤器囊袋感染的一个罕见病例报告
Stefano Maffè,Paola Paffoni,Luca Bergamasco et al.
Stefano Maffè et al.
We report an unusual case of an elderly man presenting with formation and rupture of an epidermal inclusion cyst at the level of an implantable cardiac defibrillator (ICD) pocket. The lesion appeared 2 years after ICD implantation, mimickin...
[Surgical results of tetralogy of Fallot repair with pulmonary valve preservation techniques] [0.03%]
法洛四联症根治术中保留肺动脉瓣的手术效果分析
Alvise Guariento,Claudia Cattapan,Francesco Galliotto et al.
Alvise Guariento et al.
Background: The long-term complications arising from chronic pulmonary insufficiency after surgical correction of tetralogy of Fallot (TOF) are well documented. In our center, innovative techniques for pulmonary valve (PV...
[The ETNA-AF Europe registry: 4-year data of edoxaban use in atrial fibrillation in the Italian real world compared to the European cohort] [0.03%]
恩利克斯研究（ETNA-AF）：与欧洲人群相比，达比加群在意大利真实世界中治疗房颤4年的用药情况
Letizia Riva,Giuseppe Andò,Maurizio Anselmi et al.
Letizia Riva et al.
Background: The prospective, single-arm, observational, phase 4 ETNA-AF Europe study collected real-world data about safety, effectiveness and therapeutic adherence in European patients with non-valvular atrial fibrillati...
Observational Study
Giornale italiano di cardiologia (2006). 2024 Nov;25(11):819-832. DOI:10.1714/0000.43289 2024
[NNT and NNH: statistics and stochastics in the evaluation of added therapeutic value] [0.03%]
[numbers needed to treat and numbers needed to harm：评价治疗额外价值的统计学和随机性]
Silvio Garattini,Roberto Latini,Franco Cosmi
Silvio Garattini
Any pharmacological, invasive, surgical health intervention should have an added therapeutic value as well as the requirements of quality, safety, efficacy, to be considered as a medical device based on scientific evidence and of clinical u...
[The use of PROMs (patient-reported outcome measures) and PREMs (patient-reported experience measures) in Cardiology: current state and applications to improve patient care] [0.03%]
心血管疾病领域中PROMS和PREMS的使用：现状及改善患者治疗的运用能力
Michela Barisone,Filippo Quattrone,Alberto Aimo et al.
Michela Barisone et al.
The integration of patient-reported outcomes and experiences through PROMs and PREMs tools represents a significant evolution in the quality of care and clinical practice. This article reviews the state of the art and the application experi...
Maristella Belfiori,Francesco Palmas,Camilla Podda et al.
Maristella Belfiori et al.
Heart failure (HF) guidelines have recently introduced several innovations in pharmacological therapeutic options. Specifically, for HF with reduced ejection fraction, an intensive therapeutic strategy of early initiation and rapid up-titra...
Vito Altamura,Gian Francesco Mureddu,Roberto Ceravolo et al.
Vito Altamura et al.
Despite its high worldwide prevalence and the intuitable negative prognostic connotation, for a long time peripheral artery disease (PAD) has not been the subject of particular interest by the cardiac scientific community. The availability ...